1AmeilJ, HimhJ,Poller L,et al.The pharmacology and management of the vitamin K antagonists:the Seventh ACCP Conference On Antithmmbotic and Thrombolytic Therapy[J].chest, 2004,126(3 Suppl):204S-233S.
8Taube J,Halsall D,Baqlin T.Influence of cytochrome P2450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over anticoagulation in patients on long2term treatment.Blood,2000,96(5):1816-1819
9Aithal G P,Day C P,Kesteven P J,et al.Association of polymorphisms in the cytochrome P450 CYP2C9 with wadarin dose requirement and risk of bleeding complications Lancet,1999,353(9154):717-719
10Margaglione M,Colaizzo D,D'Andrea G,et al.Genetic modulation of oral anticoagulation with warfarin.Throm b Haem ost,2000,84(5):775-778
3Melotti B, Martoni AA.Gemcitabine (EM) (dayl-8) plus carboplatin (CBDCA) (days) for the treatment of advanced non-small cell lung cancer in elderly or poor performance status patients[J]. J Clin Oncol , 2007,25 : 18 116.
5Miao LY, Yang J, Huang C1, et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing re.hen in Chinese patients[J]. EurJ Clin Pharmacol, 2007, 63(12): 1135-1141.
